Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,455
Change Today 0.00 / 0.00%
Volume 0.0
As of 10:24 AM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

kamada ltd (KMDA) Snapshot

Open
$1,477
Previous Close
$1,461
Day High
$1,498
Day Low
$1,453
52 Week High
08/12/14 - $2,596
52 Week Low
11/25/14 - $1,160
Market Cap
529.4M
Average Volume 10 Days
32.4K
EPS TTM
$-0.24
Shares Outstanding
36.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KAMADA LTD (KMDA)

kamada ltd (KMDA) Related Businessweek News

No Related Businessweek News Found

kamada ltd (KMDA) Details

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company’s lung disease products include Glassia used in augmentation and maintenance therapy in adults with emphysema due to congenital AAT deficiency (AATD); Bramitob to manage chronic pulmonary infection; and FOSTER for regular treatment of asthma. Its immunoglobulin products comprise KamRAB for prophylaxis against rabies infection; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho(D)IV for immune thermobocytopunic purpura; snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus; IVIG 5% for the treatment of various immunodeficiency-related conditions; Hepatect CP, a hepatitis B immunoglobulin; Megalotect, a CMV immunoglobulin; and Varitect, a varicella zoster immunoglobulin. The company also provides critical care products, such as Heparin Lock Flush to maintain patency of indwelling IV catheter; Heparin sodium injection to treat thrombo-embolic disorders; Kamacaine 0.5% used as anesthesia or analgesia for surgery, diagnostic, therapeutic, and obstetrical procedures, as well as spinal anesthesia for surgery; and Albumin for maintenance of circulating blood volume. In addition, it offers Transferrin for diagnostic assays and cell cultures; and coagulation factors, including Factor VIII, Factor IX, and Human Transferrin. Further, the company develops various inhaled formulations of AAT to treat AATD, cystic fibrosis, bronchiectasis, type-1 diabetes, chronic obstructive pulmonary diseases, graft-versus-host diseases, and transplantations. It has collaboration partnerships with PARI and Baxter Healthcare Corporation. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. was founded in 1990 and is headquartered in Ness Ziona, Israel.

302 Employees
Last Reported Date: 04/28/15
Founded in 1990

kamada ltd (KMDA) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: $207.0K
Co-Founder and Deputy Executive Chairman
Total Annual Compensation: $455.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $234.0K
Senior Vice President of Operations
Total Annual Compensation: $242.0K
Vice President of Research and Development
Total Annual Compensation: $212.0K
Compensation as of Fiscal Year 2014.

kamada ltd (KMDA) Key Developments

Kamada Ltd., Q2 2015 Earnings Call, Jul 30, 2015

Kamada Ltd., Q2 2015 Earnings Call, Jul 30, 2015

Kamada Ltd. Announces Revenue Results for the First Half of 2015

Kamada Ltd. announced revenue results for the first half of 2015. For the period, the company reported revenues of USD 28 million (EUR 25.3 million) for the first half of 2015. Revenue from proprietary products, in particular, stood at about USD 16 million in the period, meaning the company is well on track to achieve its annual target for sales of its products Glassia.

Kamada Ltd. Affirms Revenue Guidance for the Full Year of 2015

Kamada Ltd. affirmed revenue guidance for the full year of 2015. for the period, the company affirms revenue guidance in the range of $70 million to $73 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KMDA:IT 1,455.00 0.00

KMDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Grifols SA €40.55 EUR +0.255
View Industry Companies
 

Industry Analysis

KMDA

Industry Average

Valuation KMDA Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KAMADA LTD, please visit www.kamada.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.